AuraVax and University of Houston Sign Exclusive IP Licensing Agreement

shot by IP News Shots / 6:09 pm on 04 February, 2021

AuraVax Therapeutics Inc. has signed an exclusive licensing agreement with the University of Houston for intellectual property relating to a new intranasal vaccine and STING agonist technologies. The intranasal vaccine has the potential to be used in developing immunity towards COVID-19 and other viruses.

Read More at: https://www.biospace.com/article/releases/auravax-therapeutics-enters-into-exclusive-license-agreement-with-the-university-of-houston-for-intranasal-vaccine-and-therapeutics-technology-platform/

 

Industry: Biotechnology

Capricor and Johns Hopkins University Sign Licensing Deal for COVID-19 Test Platform’s IP and Know-How

shot by IP News Shots / 6:40 pm on 02 February, 2021

Capricor Therapeutics Inc. has entered into a licensing deal for the intellectual property, data and know-how of a COVID-19 serology test platform from Johns Hopkins University. Capricor will work towards the clinical development of the novel imaging-based serology test platform for COVID-19.

Read More at: https://seekingalpha.com/news/3656663-capricor-signs-intellectual-property-license-for-covid-19-serology-test-platform

Industry: Biotechnology

Denton and 4Wave Sign Exclusive Patent and IP Licensing Agreement

shot by IP News Shots / 6:30 pm on 27 January, 2021

Denton Vacuum LLC and 4Wave Inc. have entered into an exclusive licensing deal for the IP, patents as well as process patents of ion beam deposition and etch technologies.

Read More at: https://www.prnewswire.com/news-releases/denton-vacuum-acquires-4wave-ion-beam-portfolio-301215289.html

Industry: Others

AuraVax and MGH Sign Exclusive Licensing Agreement for IP and Technology Rights

shot by IP News Shots / 6:06 pm on 14 January, 2021

AuraVax Therapeutics Inc. and Massachusetts General Hospital (MGH) have entered into an exclusive licensing agreement for certain intellectual property and technology rights relating to compositions and discoveries of liposomal STING agonists. The agreement will help in the development of AuraVax’s lead intranasal vaccine for COVID-19 and will also help in strengthening the platform for developing therapies to target certain other viral infections.

Read More at: https://www.prnewswire.com/news-releases/auravax-therapeutics-enters-into-exclusive-license-agreement-with-massachusetts-general-hospital-for-intranasal-vaccine-and-therapeutics-platform-301205586.html

 

Industry: Pharmaceuticals

Xbrane Hopes to Renegotiate Existing IP Agreement Terms with Vaxiion

shot by IP News Shots / 8:55 pm on 06 January, 2021

In order to be able to expand marketing authorizations in EU and the US for its Xlucane Ranibizumab biosimilar, Xbrane Biopharma AB has reworked the terms of an IP licensing agreement previously signed with Vaxiion Therapeutics Inc. The renegotiated agreement also touches upon payment of royalties up to February 2024.

Read More at: https://generics.pharmaintelligence.informa.com/GB150552/Ranibizumab-Developer-Xbrane-Renegotiates-IP-Agreement-In-Landmark-Year

Industry: Pharmaceuticals

Sosei to Regain Global Rights to Muscarinic Agonist Program

shot by IP News Shots / 8:14 pm on 06 January, 2021

Sosei Group Corporation has announced that it has regained global rights to their own muscarinic agonist programs, which were licensed to Allergan Inc. After Allergan was acquired by AbbVie Inc., the acquiring company decided to return the rights due to business decisions relating to their pipeline strategy.

Read More at: https://www.pharmiweb.com/press-release/2021-01-05/sosei-heptares-to-regain-worldwide-rights-to-muscarinic-agonist-programs

Industry: Pharmaceuticals